GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Piotroski F-Score

Amoy Diagnostics Co (SZSE:300685) Piotroski F-Score : 7 (As of Apr. 19, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amoy Diagnostics Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Amoy Diagnostics Co's Piotroski F-Score or its related term are showing as below:

SZSE:300685' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 7

During the past 12 years, the highest Piotroski F-Score of Amoy Diagnostics Co was 8. The lowest was 3. And the median was 6.


Amoy Diagnostics Co Piotroski F-Score Historical Data

The historical data trend for Amoy Diagnostics Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Piotroski F-Score Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 6.00 4.00 6.00

Amoy Diagnostics Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 6.00 7.00 6.00 7.00

Competitive Comparison of Amoy Diagnostics Co's Piotroski F-Score

For the Diagnostics & Research subindustry, Amoy Diagnostics Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amoy Diagnostics Co's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Amoy Diagnostics Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Amoy Diagnostics Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 87.751 + 64.199 + 79.657 + 83.414 = ¥315 Mil.
Cash Flow from Operations was 83.466 + 80.578 + 58.571 + 101.134 = ¥324 Mil.
Revenue was 335.915 + 233.289 + 309.729 + 304.95 = ¥1,184 Mil.
Gross Profit was 284.652 + 197.031 + 265.365 + 256.131 = ¥1,003 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(1767.905 + 1934.882 + 1974.358 + 1988.208 + 2035.595) / 5 = ¥1940.1896 Mil.
Total Assets at the begining of this year (Sep23) was ¥1,768 Mil.
Long-Term Debt & Capital Lease Obligation was ¥3 Mil.
Total Current Assets was ¥1,743 Mil.
Total Current Liabilities was ¥216 Mil.
Net Income was 39.585 + 57.317 + 69.444 + 46.972 = ¥213 Mil.

Revenue was 242.921 + 195.164 + 263.542 + 248.885 = ¥951 Mil.
Gross Profit was 195.538 + 163.683 + 219.87 + 208.008 = ¥787 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(1631.372 + 1650.925 + 1671.422 + 1711.46 + 1767.905) / 5 = ¥1686.6168 Mil.
Total Assets at the begining of last year (Sep22) was ¥1,631 Mil.
Long-Term Debt & Capital Lease Obligation was ¥48 Mil.
Total Current Assets was ¥1,427 Mil.
Total Current Liabilities was ¥102 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amoy Diagnostics Co's current Net Income (TTM) was 315. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Amoy Diagnostics Co's current Cash Flow from Operations (TTM) was 324. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=315.021/1767.905
=0.17818887

ROA (Last Year)=Net Income/Total Assets (Sep22)
=213.318/1631.372
=0.13075988

Amoy Diagnostics Co's return on assets of this year was 0.17818887. Amoy Diagnostics Co's return on assets of last year was 0.13075988. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Amoy Diagnostics Co's current Net Income (TTM) was 315. Amoy Diagnostics Co's current Cash Flow from Operations (TTM) was 324. ==> 324 > 315 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=2.737/1940.1896
=0.00141069

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=47.6/1686.6168
=0.02822218

Amoy Diagnostics Co's gearing of this year was 0.00141069. Amoy Diagnostics Co's gearing of last year was 0.02822218. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=1743.106/216.319
=8.05803466

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=1426.795/102.119
=13.97188574

Amoy Diagnostics Co's current ratio of this year was 8.05803466. Amoy Diagnostics Co's current ratio of last year was 13.97188574. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Amoy Diagnostics Co's number of shares in issue this year was 396.958. Amoy Diagnostics Co's number of shares in issue last year was 392.288. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1003.179/1183.883
=0.8473633

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=787.099/950.512
=0.82807897

Amoy Diagnostics Co's gross margin of this year was 0.8473633. Amoy Diagnostics Co's gross margin of last year was 0.82807897. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=1183.883/1767.905
=0.66965306

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=950.512/1631.372
=0.58264577

Amoy Diagnostics Co's asset turnover of this year was 0.66965306. Amoy Diagnostics Co's asset turnover of last year was 0.58264577. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Amoy Diagnostics Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Amoy Diagnostics Co  (SZSE:300685) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Amoy Diagnostics Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Amoy Diagnostics Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Amoy Diagnostics Co Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co Headlines

No Headlines